Aclaris Therapeutics (ACRS) Cost of Revenue: 2017-2025
Historic Cost of Revenue for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $538,000.
- Aclaris Therapeutics' Cost of Revenue fell 17.74% to $538,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 19.49%. This contributed to the annual value of $2.8 million for FY2024, which is 18.43% down from last year.
- Latest data reveals that Aclaris Therapeutics reported Cost of Revenue of $538,000 as of Q3 2025, which was up 4.47% from $515,000 recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Cost of Revenue ranged from a high of $1.3 million in Q2 2021 and a low of $506,000 during Q1 2025.
- In the last 3 years, Aclaris Therapeutics' Cost of Revenue had a median value of $705,000 in 2024 and averaged $706,727.
- The largest annual percentage gain for Aclaris Therapeutics' Cost of Revenue in the last 5 years was 0.12% (2024), contrasted with its biggest fall of 40.12% (2024).
- Quarterly analysis of 5 years shows Aclaris Therapeutics' Cost of Revenue stood at $1.1 million in 2021, then dropped by 23.67% to $877,000 in 2022, then decreased by 17.33% to $725,000 in 2023, then decreased by 2.76% to $705,000 in 2024, then fell by 17.74% to $538,000 in 2025.
- Its last three reported values are $538,000 in Q3 2025, $515,000 for Q2 2025, and $506,000 during Q1 2025.